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Abstract
Purpose The objective of this study was to compare the
diagnostic performance of positron emission tomography
(PET), PET/CT, CT and MRI as whole-body imaging
modalities for the detection of local and/or distant recurrent
disease in colorectal cancer (CRC) patients who have a
(high) suspicion of recurrent disease, based on clinical
findings or rise in carcinoembryonic antigen (CEA).
Methods A meta-analysis was undertaken. PubMed and
Embase were searched for studies on the accuracy of
whole-body imaging for patients with suspected local and/
or distant recurrence of their CRC. Additionally, studies
had to have included at least 20 patients with CRC and 2×2
contingency tables had to be provided or derivable. Articles
evaluating only local recurrence or liver metastasis were
excluded. Summary receiver-operating characteristic (ROC)
curves were constructed from the data on sensitivity and
specificity of individual studies and pooled estimates of
diagnostic odds ratios (DORs) and areas under the ROC
curve (AUCs) were calculated. To test for heterogeneity the
Cochran Q test was used.
Results Fourteen observational studies were included
which evaluated PET, PET/CT, CT and/or MRI. Study
results were available in 12 studies for PET, in 5 studies for
CT, in 5 studies for PET/CT and in 1 study for MRI. AUCs
for PET, PET/CT and CT were 0.94 (0.90–0.97), 0.94
(0.87–0.98) and 0.83 (0.72–0.90), respectively. In patient
based analyses PET/CT had a higher diagnostic perfor-
mance than PETwith an AUC of 0.95 (0.89–0.97) for PET/
CT vs 0.92 (0.86–0.96) for PET.
Conclusion Both whole-body PET and PET/CT are very
accurate for the detection of local and/or distant recurrent
disease in CRC patients with a (high) suspicion of recurrent
disease. CT has the lowest diagnostic performance. This
difference is probably mainly due to the lower accuracy of
CT for detection of extrahepatic metastases (including local
recurrence). For clinical practice PET/CT might be the
modality of choice when evaluating patients with a (high)
suspicion of recurrent disease, because of its best perfor-
mance in patient based analyses and confident prediction of
disease status.
Keywords Colorectal cancer.Whole-body imaging.
Recurrence.Staging
Introduction
Nineteen per cent of patients with colorectal cancer are
diagnosed with distant metastasis at initial presentation,
which (when undertreated) is associated with a 5-year
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DOI 10.1007/s00259-011-1785-1survival rate of 7% [1]. Furthermore, local and distant
recurrences occur in 30–50% of patients during follow-up
after primary surgery [2]. Whereas in many patients
metastatic disease cannot be cured, in carefully selected
patients a resection of the metastases has been reported to
result in 5-year survival rates up to 30–40% [3]. The
therapeutic options for colorectal metastases—including
surgery and chemotherapy—as well as the clinical
outcome depend strongly on accurate evaluation and
early identification of recurrent lesions.
Metastatic disease in colorectal cancer is most common
in liver and lung, but can affect the whole body. Whole-
body imaging is important in different clinical settings.
First, at primary staging of colorectal cancer it is important
to determine the local and distant spread of the tumour to
determine the risk profile and the indicated treatment.
Second, whole-body imaging can be used either as part of a
surveillance programme after surgery for colorectal cancer
or when a recurrence is suspected on the basis of clinical
examinations. In the clinical setting in which patients have
suspected recurrence, it is unclear which whole-body
staging modality is most accurate for the detection of a
recurrence. Currently, in this specific setting, computed
tomography (CT) is used to detect recurrence, even though
CT has a high false-positive rate for pulmonary lesions and
high false-negative rate for extrahepatic intra-abdominal
lesions (e.g. para-aortic nodes) [4, 5]. Several studies
have reported good results for whole-body staging with
18F-fluorodeoxyglucose (FDG) positron emission tomog-
raphy (PET) and FDG PET/CT [6–8]. The experience with
magnetic resonance imaging (MRI) is limited.
So far, there is no consensus on which is the most
accurate whole-body imaging technique for colorectal
cancer patients who have a suspicion of recurrence based
on clinical findings or rise in carcinoembryonic antigen
(CEA). Therefore, the objective of the present study is to
perform a meta-analysis of published studies in order to
determine which is the most accurate whole-body imaging
modality for the detection of recurrent disease in patients
with colorectal cancer who have suspected local and/or
distant recurrent disease and to advise which modality is
most suitable in clinical practice.
Materials and methods
A literature search was performed in PubMed/MEDLINE
and Embase up to May 2010 using the following search
terms: ‘colorectal neoplasm or carcinoma or cancer’,
‘whole-body imaging or staging’, ‘neoplasm staging’,
‘colorectal’, ‘metastasis’, ‘recurrence’, ‘positron emission
tomography’ or ‘PET’, ‘magnetic resonance imaging’ or
‘MRI’, ‘computed tomography’ or ‘CT’ and ‘PET-CT’ or
‘PET/CT’. PET refers to FDG PET. No language restriction
was used. Studies were included when they met the
following criteria: (1) focus on metastasis and/or recurrence
detection in patients with suspected recurrence in the
follow-up for colorectal cancer, (2) study population
included more than 20 patients with colorectal cancer, (3)
results were given in a 2×2 contingency table or this table
could otherwise be derived from the article and (4)
reference standard combined histology with follow-up.
Case reports, reviews, articles thatevaluated local staging only
or detection of liver metastases only and studies that evaluated
whole-body imaging at primary staging or for patients with
known hepatic metastases were excluded. Last, studies which
evaluated response to therapy only were also excluded.
Two reviewers (IJGR and MM) independently searched
the databases for eligible studies. The reviewers checked
the titles and abstracts of the identified studies in order to
select studies which potentially met the inclusion criteria.
Thereafter they independently studied full text copies of the
selectedstudies to makea decisionastowhichstudies met the
inclusion criteria. In case of disagreement, consensus was
reached. Reference lists were checked to find additional
eligible studies. Data which were extracted from the studies
were: (1) number, gender and age of patients, (2) study
objective, (3) type of reference standard, (4) unit of analysis
(lesion or patient based analysis), (5) degree of blinding, (6)
duration of follow-up and (7) prevalence of disease. Study
quality was assessed with the QUADAS checklist for studies
of diagnostic accuracy included in systematic reviews [9].
Statistical analysis
Preferably, results from lesion based analyses were used for
this meta-analysis, but part of the studies only reported data
on a patient basis. Based on the results from the (derived)
2×2 contingency tables, pooled measures for diagnostic
performance, such as sensitivity, specificity, diagnostic
odds ratio (DOR) and area under the receiver-operating
characteristic (ROC) curve (AUC), were calculated using
random effects models. The pooled DOR for each imaging
modality was used for the construction of summary ROC
(SROC) curves. SROC curves account for the so-called
threshold effect in diagnostic studies, which arises when
studies use different cutoff points or thresholds to define a
positive or negative test result. The DORs combine
sensitivity and specificity into one measure for diagnostic
performance. A DOR of 1 means that the test has no ability
to discriminate. The higher the DOR, the better the ability
of a test to discriminate between subjects with and without
the disease of interest. To test differences in diagnostic
performance between modalities for statistical significance,
the relative DOR of one modality compared to another was
calculated with its corresponding p value.
Eur J Nucl Med Mol Imaging (2011) 38:1560–1571 1561The Cochran Q test was used to test for heterogeneity
between individual study results. Significance of this test
indicatesthatdifferencesbetweenstudyresultscannotsolelybe
attributed to sampling variation. The p value for heterogeneity
was considered significant when p<0.10, because heteroge-
neity tests are known for their lack of statistical power.
Differences in DORs between studies can also result from
differences in design, case mix and analysis. To account for
heterogeneity, the DOR and AUC for the imaging modalities
under study were pooled within subgroups of studies. These
subgroups were made according to the presence or absence of
a specific study characteristic that can affect the estimate of
the diagnostic performance of a modality.
Pooled estimates of diagnostic performance and relative
DORs were calculated with Meta-DiSc version 1.4[10], a
software programme which implements meta-regression
using a generalization of a model that was proposed by
Moses et al. [11].
Results
With the search 82 studies were retrieved, of which a total
of 60 articles potentially met the inclusion criteria after
selection based on titles and abstracts. Of these 60 articles,
46 were excluded[12–56], leaving 14 articles for inclusion
[2, 6–8, 57–66]. The 46 articles were excluded because of
the following reasons. Twenty articles studied patients with
primary colorectal cancer or patients with known hepatic
metastases [13, 14, 16, 18, 20, 21, 23, 25, 29, 30, 33–36,
38, 40, 41, 44, 55, 56]. Nine studies were excluded because
they included less than 20 patients with colorectal cancer
[12, 15, 19, 22, 24, 26, 31, 32, 50]. Six articles were
excluded because a 2×2 contingency table could not be
constructed [28, 39, 43, 45, 53, 54], five evaluated patients
after recent treatment with chemotherapy or evaluated
response after treatment and were therefore excluded [17,
27, 37, 42, 49] and three were a meta-analysis and/or
review [47, 48, 52]. One was a case report [51]. One article
evaluated the accuracy of a combination of diagnostic
modalities to detect lesions without specifying individual
accuracies per modality and was thus excluded [46]. Finally,
one study was excluded because it only evaluated the clinical
reports for PET and did not re-evaluate the images for the
study [67]. Study identification and inclusion are shown in a
flowchart in Fig. 1. Results of the quality assessment with
the QUADAS checklist are shown in Table 1.
IndividualstudycharacteristicsarepresentedinTable2.O f
the 14 articles included, 3 studied a single modality [2, 8, 62]
and 11 compared two or three different modalities [6, 7, 57–
61, 63–66]. Grouping the articles according to investigated
imaging modality, 12 articles studied the performance of
PET [6–8, 57–62, 64–66], 7 articles studied the performance
of CT [6, 8, 57, 59, 61, 64, 66], 5 articles studied the
performance of PET/CT [2, 7, 58, 61, 63]a n d1a r t i c l e
studied the performance of MRI [63]. In two studies which
evaluated both PET and CT only part of the thorax and
abdomen was imaged with CT and therefore only the results
for PET were included from these studies [59, 66]. So, in
total results from five studies were available for CT. All CT
studies used intravenous contrast. The number of patients
ranged from 24 to 115 patients per study, with a total of 861
Fig. 1 PRISMA flowchart
describing the identification
and inclusion of studies
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1564 Eur J Nucl Med Mol Imaging (2011) 38:1560–1571patients evaluated in all included studies. The percentage of
male patients varied from 46 to 71% and the mean or median
a g er a n g e df r o m5 8t o6 8y e a r s .A l ls t u d i e su s e d
histopathology or a combination of histopathology, clinical
and radiological follow-up, conventional diagnostic modal-
ities (X-ray, endoscopy, ultrasound) and surgical exploration
as reference method. The indication for whole-body imaging
was suspected local or distant recurrence based on clinical
symptoms, rise in CEA levels, endoscopy findings or
findings from other imaging methods in all studies for all
or the majority of patients.
Estimates of diagnostic performance, such as sensitivity,
specificity, positive and negative predictive value, accuracy,
DOR and AUC for all individual studies are shown in Table 3.
Summary receiver-operating characteristic curves
SROC curves for the diagnostic performance of PET, PET/
CT and CT and the individual study results are shown in
Fig. 2. PET and PET/CT had the best diagnostic perfor-
mance for recurrence detection, with DORs of 55.2 [95%
confidence interval (CI) 23.2–131.2] and 55.3 (95% CI
15.9–191.8), respectively, compared to a DOR of 9.8 (95%
CI 4.2–22.8) for CT. The single study concerning MRI was
not included in the regression analysis but the results are
shown in the graph as a single value. The DOR for this
MRI study was 35.1 (95% CI 13.5–90.4). The
corresponding AUCs for PET, PET/CT and CT for
recurrence detection were 0.94 (95% CI 0.90–0.97), 0.94
(95% CI 0.87–0.98) and 0.83 (95% CI 0.72–0.90),
respectively. CT had a significantly lower diagnostic
performance than PET (p=0.021). Between CT and PET/
CT the difference was not significant (p=0.10). The
difference between PET and PET/CT was not significant
either (p=0.66). The AUC for the single MRI study was
0.92 (95% CI 0.86–0.96). Pooled sensitivity and specificity,
AUC and DOR for the modalities are shown in Fig. 3.
Subgroup analyses
The Cochran Q test showed that there is significant
heterogeneity between study results for each imaging
Table 3 Diagnostic performance for all the included studies, sorted by modality
Author Modality Unit of analysis Sensitivity Specificity PPV NPV Accuracy DOR
Arulampalam et al. (2001) [57] PET PbP 93 58 85 78 83 16
Cohade et al. (2003) [58] PET LbL 88 56 92 43 83 8
Delbeke et al. (1997) [59] PET Both 94 86 97 73 92 74
Imbriaco et al. (2000) [6] PET LbL 94 95 96 93 95 222
Kim et al. (2005) [7] PET Both 74 93 77 92 88 33
Lonneux et al. (2002) [60] PET Both 97 73 96 80 94 465
Nakamoto et al. (2007) [61] PET PbP 75 82 84 71 78 12
Ruhlmann et al. (1997) [62] PET PbP 100 75 94 100 95 236
Staib et al. (2000) [64] PET PbP 98 91 93 98 95 328
Valk et al. (1999) [65] PET PbP 96 71 96 71 93 51
Whiteford et al. (2000) [66] PET PbP 87 68 92 58 84 697
Willkomm et al. (2000) [8] PET PbP 100 100 100 100 100 14
Arulampalam et al. (2001) [57] CT PbP 73 75 88 53 74 7
Imbriaco et al. (2000) [6] CT LbL 74 70 77 67 72 6
Nakamoto et al. (2007) [61] CT PbP 69 93 93 69 79 51
Staib et al. (2000) [64] CT PbP 91 72 80 87 82 22
Valk et al. (1999) [65] CT PbP 78 50 92 24 75 4
Chen et al. (2007) [2] PET/CT PbP 95 83 96 77 93 64
Cohade et al. (2003) [58] PET/CT LbL 86 67 94 44 83 11
Kim et al. (2005) [7] PET/CT Both 89 98 94 96 96 298
Nakamoto et al. (2007) [61] PET/CT PbP 75 96 96 74 84 23
Schmidt et al. (2009) [63] PET/CT Both 86 97 96 88 91 136
Schmidt et al. (2009) [63] MRI Both 73 93 90 79 83 35
If both lesion based and patient based results were provided, results for lesion based analyses are shown in this table
PET positron emission tomography, CT computed tomography, PET/CT positron emission tomography combined with computed tomography,
MRI magnetic resonance imaging, PPV positive predictive value, NPV negative predictive value, PbP patient-by-patient based analysis, LbL
lesion-by-lesion based analysis
Eur J Nucl Med Mol Imaging (2011) 38:1560–1571 1565modality (p<0.10). This heterogeneity is also illustrated in
Fig. 2, which shows substantial scatter of observed pairs of
sensitivity and specificity of individual studies around the
fitted SROC curves. To correct for potential sources of
heterogeneity subgroup analyses were performed. Pooled
estimates of diagnostic performance were calculated within
subsets of studies that differed with respect to factors that
potentially can affect diagnostic performance: (1) unit of
analysis (patient based versus lesion based), (2) prevalence
(percentage of patients with malignant disease in the
studied population) as an indicator of disease spectrum
(<75% versus ≥75%), (3) blinding to clinical information
(yes versus no), (4) design (retrospective versus prospec-
tive) and (5) year of publication (<2003 versus ≥2003). Full
blinding was defined as blinding to both clinical informa-
tion and other imaging results. Partial blinding was defined
as blinding for other imaging results only. In all subgroups
CT remained the modality with the lowest diagnostic
performance. The results of the subgroup analyses are
displayed in Fig. 4. PET had a significantly lower
diagnostic performance when a study was published after
2003: AUC was 0.96 (95% CI 0.92–0.98) before 2003 vs
0.87 (95% CI 0.78–0.92) after 2003, p=0.013.
Discussion
In this meta-analysis we compared PET, PET/CT, CT and
MRI for whole-body staging in patients who have
suspected recurrence in the follow-up for curatively treated
Fig. 2 SROC curves with all
individual study results for all
modalities. The single study
on MRI is displayed as a single
value in the graph. PET (n=12),
CT (n=5), PET/CT (n=5),
MRI (n=1)
Fig. 3 Pooled sensitivity (%)
and specificity (%), area under
the ROC curve (AUC, %) and
diagnostic odds ratio (DOR)
for CT, PET and PET/CT with
95% confidence intervals
indicated by error bars
1566 Eur J Nucl Med Mol Imaging (2011) 38:1560–1571colorectal cancer. We found that PET and PET/CT have a
high diagnostic performance with an AUC of 0.94 for both
PET and PET/CT. CT had a significantly lower diagnostic
performance than PET or PET/CT with an AUC of 0.83.
This lower diagnostic performance persisted after correc-
tion for differences in design and analysis of studies. The
subgroup analyses showed that in studies in which
readers were fully blinded (to both clinical information
and other imaging results) or in studies which were
published after 2003 the diagnostic performance was
lower for PET. The single study evaluating MRI showed
a high AUC of 0.92.
PET and PET/CT were the most accurate modalities.
PET and PET/CT are metabolic imaging techniques that
provide information on the nature of a lesion based on
differences in glucose metabolism. Malignant lesions have
a higher glucose metabolism and thus a higher uptake of
FDG. These changes in metabolism are known to precede
changes in morphology (which are evaluated with CT),
hence the higher sensitivity for PET or PET/CT than for CT
in the detection of small malignant lesions. In Fig. 5 an
illustration is given of a lesion with high FDG uptake (and
thus detection with PET) which could not (yet) be identified
with CT. FDG uptake is also increased in inflammatory
tissue and in normal organs such as the brain, the urinary
tract and bowel, causing false-positive findings. By
combining the functional information of PET with the
morphological information of CT false-positive errors can
be reduced and superior performance of PET/CT over PET
and CT as stand alone techniques is expected. Nevertheless,
the results of our meta-analysis do not confirm superior
performance for PET/CT over PET. There are some
methodological issues related to this finding. Only three
studies compared PET/CTwith PETwithin the same patient
group and therefore most of the data originated from studies
without direct comparison of both modalities in the same
patients [7, 58, 61]. Differences in study designs between
the PET and PET/CT studies could have influenced the
results and this may have favoured the performance of PET.
The results of the three studies that did compare PET with
PET/CT in the same study population showed a superior
performance for PET/CT, especially in the patient based
analyses [7, 58, 61]. In our subgroup analyses of patient
based study results we could confirm the higher perfor-
mance of PET/CT over PET on a patient basis (AUC 0.95
for PET/CT vs 0.92 for PET, Fig. 4). The three studies also
Fig. 4 Areas under the SROC curve with 95% confidence intervals
(error bars) per modality for subgroups. Prevalence refers to the
prevalence of disease in the studied population. Fully blinded is defined
as reading the images without any knowledge about the patient. Clinical
info indicates that readers were aware of clinical information about the
patients, but had no knowledge about results from other imaging
studies. In some subgroups columns are missing for one or more
modalities, because no or only one study was available for that
subgroup and thus the subgroup analysis could not be performed
Fig. 5 Diagnostic CT image
(left) and PET image (right)
of a patient who has a clearly
visualised para-aortic lesion
on PET (arrow), which cannot
be discerned on CT
Eur J Nucl Med Mol Imaging (2011) 38:1560–1571 1567found that readers were more confident in their diagnosis of
lesions with PET/CT than with PET only. Kim et al.
reported highest confidence level scores for PET/CT (91%)
compared to 61% for PET and 50% for CT [7].
CT had a lower diagnostic performance than PET/CT
and PET. The cause may be that the accuracy of CT for
extrahepatic metastasis detection is lower than that of PET
and PET/CT. CT is known to be more accurate in the
detection of hepatic than in the detection of extrahepatic
metastases (including local recurrence), making it less ideal
for whole-body staging. Studies in this meta-analysis have
shown that with respect to the detection of extrahepatic
lesions CT performs worse (sensitivities 53–71% and
specificities 50–85%) than PET (sensitivities 70–100%
and specificities 40–100%) [59, 61, 66]. Several older
studies have reported a low diagnostic performance for the
detection of local recurrence with CT [68, 69]. A more
recent study by Stückle et al. with multislice CT acknowl-
edged the low sensitivity (38–82%) for local recurrence
detection but reported high specificity (97–100%) in the
follow-up after surgery [70]. Because the studied popula-
tions in our meta-analysis comprised patients who had both
local and distant recurrence, the diagnostic performance of
CT can be influenced by the fact that local recurrence
detection is difficult with CT (Fig. 6).
Finally, most included studies evaluating whole-body
CT were performed around the year 2000 and it should be
taken into account that since then the quality of CT may
have improved considerably. This may have caused
underestimation of the diagnostic performance of CT in
this meta-analysis. However, a more recent study (2007)
comparing a modern CT technique with PET and PET/CT
within the same patient population by Nakamoto et al. still
showed that CT had the lowest diagnostic performance,
while PET/CT was the most accurate modality.
An interesting finding in this meta-analysis is that in
more recently published studies the diagnostic performance
of PET was significantly worse than in earlier publications.
This phenomenon is observed more often in diagnostic
studies and may be explained by publication bias. In the
late 1990s PET was a relatively new modality, so the
chance for acceptance for publication was higher for
positive study results. Another possible explanation is that
study design and methodology have improved over time
leading to more critical evaluation of the modality and thus
possibly lower diagnostic performance of a modality.
Awareness of clinical information clearly improved
performance. The diagnostic performance of studies in
which readers were fully blinded was lower than in studies
in which readers were aware of all clinical information
except for results of other imaging modalities. The largest
difference was observed for PET (AUC 0.91 for full
blinding vs 0.98 in case of awareness of clinical data).
This finding is in agreement with clinical experience that
knowledge of the clinical information of the patient is
considered crucial to achieve sufficient diagnostic perfor-
mance, particularly for PET. These findings underline the
necessity for clinicians to provide radiologists and nuclear
physicians with full information about the patient’s clinical
status and the importance for radiologists and nuclear
physicians to be involved in multidisciplinary management
teams, where they are confronted with the clinical situation.
One established modality that has been used increasingly
in the last decade—in particular for the follow-up of
patients with suspected local recurrence after surgery for
rectal cancer—is MRI [71]. Although MRI has shown to be
feasible for the detection of local recurrences, its yield is
not high enough to warrant routine use in the follow-up of
rectal cancer patients [72, 73]. The single study that
evaluated whole-body MRI showed good results, but more
evidence is needed to establish the role of MRI in whole-
body imaging for colorectal cancer.
Limitations
There are some limitations to this study. The first important
issue is that this is a meta-analysis of published studies and
therefore heterogeneity between studies is present. To
account for this heterogeneity we performed subgroup
analyses according to factors that were likely to cause
heterogeneity and still found that CT had a lower diagnostic
performance than PET and PET/CT. However, because of
Fig. 6 CT image (left) and PET
image (right) of a patient with
locally recurrent colorectal can-
cer after a sigmoid resection. On
PET a clear hot spot (arrow)i s
found with increased FDG up-
take, while on CT it was not
recognised as a local recurrence
(arrow)
1568 Eur J Nucl Med Mol Imaging (2011) 38:1560–1571the relatively small number of studies per modality,
simultaneous correction for more than one study factor
was not feasible, making our level of evidence less robust.
Moreover, residual heterogeneity may have remained
unexplained due to some unmeasured or unreported study
characteristics, which is inherent to a meta-analysis based
on published data.
Second, in all studies a combination of pathology and
follow-up was used as the reference standard. However,
undetected lesions will not be discovered until they become
visible with imaging and therefore there is a chance for
verification bias. Most studies that used follow-up as the
reference standard had a follow-up time of at least 6 months.
However, small missed lesions might become visible after a
longer interval. Verification bias could then lead to over-
estimations of accuracy.
Third, because we aimed to evaluate whole-body staging
for the detection of both local and distant recurrences of
colorectal cancer in patients with suspected recurrence
based on clinical findings or rise in CEA, we excluded
studies which merely provided data on liver recurrence or
local recurrence only.
Last, most PET/CT studies in our meta-analysis used
side-by-side comparison of single PET and single CT, and
fused PET/CT was only scarcely used.
Conclusions and clinical relevance
Our study suggests that for whole-body imaging of patients
with a (high) suspicion of recurrent colorectal cancer during
follow-up PET/CT is the most accurate imaging modality,
closely followed by PET, which performs slightly lower
than PET/CT on a patient basis. CT has the lowest
diagnostic performance.
This meta-analysis explored diagnostic performance in
the clinical setting in which patients had suspected local
and/or distant recurrence based on clinical findings or a rise
in CEA. In current clinical practice CT is the most widely
used modality for this type of patients and only when CT
findings are equivocal, PET or PET/CT is performed. Our
meta-analysis shows that instead of CT as the first-line
imaging modality, PET/CT might be the recommended
modality for patients with suspected local or distant
recurrence based on clinical findings or rise in CEA. In
such patients, a negative CT result does not seem to help in
excluding a recurrence and should be followed by PET/CT
anyhow. Furthermore, when CT findings are equivocal,
PET/CT is needed to further characterise lesions and when
CT detects malignant lesions, PET/CT is obligatory to
search for additional metastases when curative surgery of
the malignant lesions is considered. However, while
interpreting these results one should keep in mind that
there were some limitations of this meta-analysis with
regard to heterogeneity and number of studies, which make
the estimate of diagnostic performance less precise and less
definitive. Furthermore, whether implementation of this
recommended diagnostic strategy is feasible in clinical
practice will also depend on the cost-effectiveness of this
approach.
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